At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03378 HANXBIO-B
Closed 09-07 16:08:15
29.500
+0.520
+1.79%
High29.500
Low28.360
Vol7.50K
Open31.000
D1 Closing28.980
Amplitude3.93%
Mkt Cap3.95B
Tradable Cap3.95B
Total Shares134.00M
T/O215.51K
T/O Rate0.01%
Tradable Shares134.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
HanxBio H1 FY26 Loss Narrows to RMB 33.24 Million; Other Income and Gains More than Doubled to RMB 27.61 Million
Hanx Biopharmaceuticals (Wuhan) Co Ltd is a China-based company mainly engaged in the research and development of immune-oncology therapies. The Company’s product pipeline comprises clinical stage drug candidates focused on oncology and preclinical stage drug candidates, including Core Product HX009 and Key Products HX301 and HX044, as well as antibody drug conjugate, bispecific antibody and monoclonal antibody for both autoimmune and oncology market. HX009 is a bifunctional anti-programmed cell death protein 1 (PD-1) antibody signal regulatory protein α (SIRPα) fusion protein developed in-house. HX301 is a multi-targeted kinase inhibitor targeting critical pathways such as colony-stimulating factor-1 receptor (CSF1R), AMPK-associated protein kinase 5 (ARK5), FMS-like tyrosine kinase 3 (FLT-3), and cell cycle-independent kinase 4/6 (CDK 4/6). HX044 is a novel bifunctional anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody SIRPα fusion protein.